Den här översättningen är inte klar ännu. Den här sidan är just nu på engelska.

Gå till den engelska sidan

Cure My Disease

Don't miss your cure!

 Log in / Sign up

New model aims to cure hepatitis c in homeless drug users

NCT ID NCT07667101

Cure Sponsor: University of Washington Source: ClinicalTrials.gov ↗

What the study statuses mean

This study's is highlighted.

Recruitment status, easiest to join first

Recruiting now This study
This trial is taking on new participants right now.
Not yet recruiting
Registered, but not yet taking participants.
By invitation only
Not open to general applications. Only people the study team invites can take part.
Paused
Paused for now. It may or may not start again.
Ongoing
Running, but no longer taking on new participants.
Completed
The trial has finished. Results may not be published yet.
Stopped early
Stopped early, before it reached the end. That can be for many reasons, including safety.
Cancelled
Cancelled before anyone took part.

Expanded access (not trials)

Expanded access
Not a trial. This treatment can be requested outside a study, case by case, for people who qualify.
Expanded access (paused)
Not a trial. The treatment can normally be requested outside a study, but is unavailable right now.
Expanded access (ended)
Not a trial. The treatment could once be requested outside a study, but no longer can.
Approved
The treatment has been approved, so it is available normally rather than through this programme.

When the status isn't known

Details not published
The full record has not been published yet, so there is little to show here.
Status unknown
This status has not been confirmed recently, so it may be out of date.

First seen Jun 27, 2026 · Last updated Jun 27, 2026

Summary

This study tests a collaborative care model where pharmacists, doctors, and patient navigators work together to provide hepatitis C treatment to people who use drugs and live in supportive housing. 444 participants will be randomly assigned to either this model or usual care. The goal is to see if this approach increases the number of people who get evaluated and cured of hepatitis C.

What this could mean

Our plain-language read of the trial. This is informational only, not medical advice or a prediction.

Active substance
Direct-acting antivirals (DAAs) for hepatitis C, plus PrEP for HIV and naloxone for overdose prevention, delivered through a pharmacist-led collaborative care model
What this could lead to
If successful, this model could cure hepatitis C in a hard-to-reach population, reducing liver disease and preventing spread of the virus.
What could go wrong
This is an implementation study, not a drug trial. Success depends on engagement and follow-up, which can be challenging in this population. The cure rate may be lower than in controlled settings.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Study facts

What this study's own registry entry says, in plain language.

Phase

Not a phased trial

Phase numbers describe drug development. The registry uses this when they do not apply, as it does for trials of devices, procedures or behaviour changes, and for observational studies.

Participants

About 444 people

The number the study aims to enrol. It can still change while the study runs.

Started

Jun 2026

Expected to finish

Jun 2029

An estimate. End dates often move.

Lead sponsor

Other sponsor

The registry's catch-all category, for sponsors it does not file as a company, a government agency, or a research network.

Who can take part

This study's own entry requirements. Only the study team can say for certain whether you qualify.

Ages

18 years and older

Sex

Anyone

Healthy volunteers

Not accepted

This study is not open to healthy volunteers. The entry requirements below say who it is open to.

Show the full entry requirements

Copied word for word from the study's registry entry, so the wording is the study team's rather than ours.

Inclusion Criteria: * Adult ≥18 years of age * Currently a resident at one of DESC's PSH buildings at the time of study enrollment * Positive HCV test documented (screening antibody test or viral load test) * Provides release of information (ROI) to access community pharmacy electronic medical records (EHR) and/or other HCV treatment providers for information on HCV care during the study period between baseline visit and 24-month visit Exclusion Criteria: * Taking medications to treat HCV at the start of the study * Cognitive impairment (acute or chronic) resulting in inability to provide informed consent * Currently or impending incarceration * People who plan to leave the Seattle area within 24 months * Not English speaking * Behavioral risk posing safety concerns per discretion of research staff

Get updates

Get notified about this study

Sign up to get updates when this study changes or when new studies for Hepatitis C (HCV) are added.

Vår säkerhetsrekommendation!

Genom att skicka in godkänner du våra Användarvillkor

Conditions

The condition(s) this trial relates to.

hepatitis C virus infection

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

Hepatitis C (HCV)

How to take part

Only the study team decides who joins. These are the ways to reach them.

  1. The places running it

    1 site. The list below names each one and where it is.

  2. The official record

    ClinicalTrials.gov lists the study team's own contact details, including names and phone numbers. We don't republish those.

    Open the record ↗

  3. A doctor treating you

    A doctor who knows your case can contact a study site on your behalf, and can tell you whether this study is worth pursuing at all.

Contacts and locations

Locations

  • Harborview Medical Center

    RECRUITING

    Seattle, Washington, 98104, United States

More trials for these conditions

Other studies related to the condition(s) this trial covers.